Results 21 to 30 of about 644,346 (303)

Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation

open access: yesJournal of Cardiovascular Development and Disease, 2022
The aim of this research was to evaluate if patients with chronic kidney disease (CKD) and mild or mild to moderate depression of renal function have an increased risk of atrial fibrillation (AF) recurrences after cryoballoon (CB) ablation.
Giuseppe Boriani   +14 more
doaj   +1 more source

Atrial fibrillation in the elderly population: Challenges and management considerations

open access: yesJournal of Arrhythmia, 2021
Importance Atrial fibrillation is the most clinically significant arrhythmia in humans when viewed both from a global and also a national perspective. In the United States, approximately 2.7‐6.1 million people are estimated to have atrial fibrillation ...
Mohammed Salih   +3 more
doaj   +1 more source

Catheter Ablation vs. Anti-Arrhythmic Drugs as First-Line Treatment in Symptomatic Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

open access: yesFrontiers in Cardiovascular Medicine, 2021
Background: Catheter ablation has become a well-established indication for long-term rhythm control in atrial fibrillation (AF) patients refractory to anti-arrhythmic drugs (AADs).
Andrea Saglietto   +4 more
doaj   +1 more source

Rhythm Control in AF: Have We Reached the Last Frontier?

open access: yesEuropean Cardiology Review, 2019
AF is a worldwide epidemic, affecting approximately 33 million people, and its rising prevalence is expected to account for increasing clinical and public health costs.
Gheorghe-Andrei Dan
doaj   +1 more source

Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness

open access: yesРациональная фармакотерапия в кардиологии, 2021
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center ...
N. Yu. Mironov   +18 more
doaj   +1 more source

STATE OF THE ART PHARMACOLOGICAL THERAPY FOR ATRIAL FIBRILLATION

open access: yesРоссийский кардиологический журнал, 2017
Pharmacological therapy remains the primary approach to atrial fibrillation (AF). Management of all AF patients includes the decision on rate or rhythm control. The latter means antiarrhythmic drugs application that are being selected primarily by safety
S. G. Kanorsky, Yu. S. Kovalenko
doaj   +1 more source

Perspectives by a position statement on atrial fibrillation in acute heart failure a: Mechanisms and therapeutic approaches

open access: yesAnatolian Journal of Cardiology, 2020
The co-existence of atrial fibrillation (AF) and acute heart failure (AHF) is frequently reported and can exacerbate either or both of them. Their combination leads to increased morbidity and mortality.
Sercan Okutucu, Bülent Görenek
doaj   +1 more source

The Challenges of Tachycardia Induced Cardiomyopathy - a Case Report [PDF]

open access: yesRomanian Journal of Cardiology, 2021
Tachycardia-induced cardiomyopathy (TIC) is characterized by reversible left ventricular dysfunction caused by long-standing tachycardia. Treatment options for tachyarrhythmias causing TIC have evolved, especially the rhythm control strategies, ensuring ...
Andreea Elena VELCEA   +2 more
doaj   +1 more source

Rhythm in the speech of a person with right hemisphere damage: Applying the pairwise variability index [PDF]

open access: yes, 2007
Although several aspects of prosody have been studied in speakers with right hemisphere damage (RHD), rhythm remains largely uninvestigated. This study compares the rhythm of an Australian English speaker with right hemisphere damage (due to a stroke ...
Abercrombie D   +30 more
core   +1 more source

Home - About - Disclaimer - Privacy